Regular Use of Fish Oil Supplements, Life's Essential 8 Score, and Cardiovascular Mortality in People With Type 2 Diabetes: A Longitudinal Cohort Study

被引:0
作者
Hua, Rong [1 ]
Lam, Chun Sing [1 ]
Chu, Natural [2 ]
Yang, Aimin [2 ,3 ]
Chow, Elaine [2 ,3 ,4 ]
Cheung, Yin Ting [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Prince Wales Hosp, Phase Clin Trial Ctr 1, Hong Kong, Peoples R China
关键词
fish oil; dietary supplements; Life; Essential; 8; cardiovascular health; type; 2; diabetes; AMERICAN HEART ASSOCIATIONS; ICOSAPENT ETHYL; DISEASE; HEALTH; ATHEROSCLEROSIS; TRIGLYCERIDES;
D O I
10.1016/j.tjnut.2024.11.012
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: To date, to our knowledge, no studies have investigated the effects of cardiovascular health on the cardioprotective benefits of fi sh oil supplementation in people with type 2 diabetes (T2D). The utility of fi sh oil in reducing risk of cardiovascular disease (CVD)-related mortality in people with diabetes remains unclear and inconsistent. Objectives: This study aimed to investigate the potential modifying effect of cardiovascular health (CVH) level, as assessed using the Life's Essential 8 (LE8) score, on the association between regular fi sh oil supplement use and CVD-relates mortality in middle-aged and older people with T2D. Methods: Participants with T2D in the UK Biobank were included. CVH level was categorized by the mean LE8 score (55 points). Multivariable-adjusted Cox models were used to evaluate the longitudinal association between regular use of fi sh oil supplements and CVD Mortality. We performed stratified analysis across different CVH levels and tested for potential interaction between fi sh oil supplement use and CVH level. Results: The analysis included 19,003 participants (mean age: 59.9 f 6.9 y, 36.1% women), of whom 39.6% were regular users of fi sh oil supplements. During a median follow-up of 13.7 y, regular use of fi sh oil supplements was significantly associated with lower risk of CVD Mortality among participants with better CVH [ie, LE8 score of >= 55 points; hazard ratio (HR): 0.65; 95% CI: 0.51, 0.84; P = 0.001)], but not among those with poorer CVH (i.e. LE8 score < 55 points; HR: 1.02; 95% CI: 0.83, 1.25; P = 0.867). The interaction between the use of fi sh oil supplements and CVH level on CVD Mortality was significant (P = 0.018). Conclusions: Middle-aged and older T2D individuals with a relatively low baseline CVH level may not obtain cardiovascular benefits from fi sh oil supplements. Our fi ndings highlight the importance of promoting multimodal lifestyle interventions to improve survival outcomes of people with T2D.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 41 条
  • [1] Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids
    Adkins, Yuriko
    Kelley, Darshan S.
    [J]. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2010, 21 (09) : 781 - 792
  • [2] Global prevalence and types of complementary and alternative medicines use amongst adults with diabetes: systematic review and meta-analysis
    Alzahrani, Abdulaziz S.
    Price, Malcolm J.
    Greenfield, Sheila M.
    Paudyal, Vibhu
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (09) : 1259 - 1274
  • [4] Introduction to the Analysis of Survival Data in the Presence of Competing Risks
    Austin, Peter C.
    Lee, Douglas S.
    Fine, Jason P.
    [J]. CIRCULATION, 2016, 133 (06) : 601 - 609
  • [5] Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies
    Ballantyne, Christie M.
    Bays, Harold E.
    Philip, Sephy
    Doyle, Ralph T., Jr.
    Braeckman, Rene A.
    Stirtan, William G.
    Soni, Paresh N.
    Juliano, Rebecca A.
    [J]. ATHEROSCLEROSIS, 2016, 253 : 81 - 87
  • [6] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    Bhatt, Deepak L.
    Steg, P. Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Ketchum, Steven B.
    Doyle, Ralph T., Jr.
    Juliano, Rebecca A.
    Jiao, Lixia
    Granowitz, Craig
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) : 11 - 22
  • [7] n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
    Bosch, Jackie
    Gerstein, Hertzel C.
    Dagenais, Gilles R.
    Diaz, Rafael
    Dyal, Leanne
    Jung, Hyejung
    Maggiono, Aldo P.
    Probstfield, Jeffrey
    Ramachandran, Ambady
    Riddle, Matthew C.
    Ryden, Lars E.
    Yusuf, Salim
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (04) : 309 - 318
  • [8] Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus
    Bowman, Louise
    Mafham, Marion
    Wallendszus, Karl
    Stevens, Will
    Buck, Georgina
    Barton, Jill
    Murphy, Kevin
    Aung, Theingi
    Haynes, Richard
    Cox, Jolyon
    Murawska, Aleksandra
    Young, Allen
    Lay, Michael
    Chen, Fang
    Sammons, Emily
    Waters, Emma
    Adler, Amanda
    Bodansky, Jonathan
    Farmer, Andrew
    McPherson, Roger
    Neil, Andrew
    Simpson, David
    Peto, Richard
    Baigent, Colin
    Collins, Rory
    Parish, Sarah
    Armitage, Jane
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (16) : 1540 - 1550
  • [9] Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
    Budoff, Matthew J.
    Bhatt, Deepak L.
    Kinninger, April
    Lakshmanan, Suvasini
    Muhlestein, Joseph B.
    Le, Viet T.
    May, Heidi T.
    Shaikh, Kashif
    Shekar, Chandana
    Roy, Sion K.
    Tayek, John
    Nelson, John R.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 (40) : 3925 - 3932
  • [10] Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? updated meta-analysis of randomized controlled trials
    Casula, Manuela
    Olmastroni, Elena
    Gazzotti, Marta
    Galimberti, Federica
    Zambon, Alberto
    Catapano, Alberico L.
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 160